REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.

Transcenta Holding Limited states that it has received the green light from FDA to continue with TranStar 301,This trial is conducted for Osemitamab (TST001) used together with Nivolumab and chemotherapy.

Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.

SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.

Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.

Purple Biotech Ltd. shares clinical insights from its dose amplification segment of the Phase 1/2 trial of NT219.

Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.

Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.

Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).

ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.

Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.

Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.